EVIMED 60 - Deus Medical

Raloxifene hydrochloride was introduced by Eli Lilly & Company. Has got FDA approval since 1997 for the treatment of osteoporosis, in postmenopausal women to support bone health efforts​. In 2007​ the FDA expanded its authorization to include breast cancer prevention for individuals at risk​. By modulating estrogen receptors​ it is able to focus on tissues​ promoting bone durability and impeding the proliferation of cancer cells, in breast tissue​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about EVIMED 60 by Deus Medical, consult with your doctor or healthcare professional.